Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JMDCFRA:6JM -1.58%80 3-Year EBITDA Growth Rate is 18.20% as of Jun. 2026, which is 21% below its 10-year median of 22.90. GuruFocus rates FRA:6JM with a GF Score™ of 80/100 and a GF Value™ of €29.78 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 525 Healthcare Providers & Services companies, JMDC ranks better than 63.62% on this metric.
During the past 12 months, JMDC's average EBITDA Per Share Growth Rate was 17.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 18.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 18.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of JMDC was 37.80% per year. The lowest was 11.00% per year. And the median was 22.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
JMDC 3-Year EBITDA Growth Rate Related Terms
FRA:6JM vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, JMDC's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JMDC 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, JMDC's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where JMDC's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 18.20% mean?
JMDC (FRA:6JM) has a 3-Year EBITDA Growth Rate of 18.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for JMDC and its competitors. This is 21% below median its historical median of 22.90. Over the past decade, JMDC's 3-Year EBITDA Growth Rate has ranged from 11.00 to 37.80. According to the industry distribution chart, JMDC ranks #191 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 36.4%.
Is JMDC's 3-Year EBITDA Growth Rate too high?
JMDC's current 3-Year EBITDA Growth Rate of 18.20% is 21% below median its 10-year median of 22.90. Over the past 10 years, this metric has ranged from a low of 11.00 to a high of 37.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. JMDC's value of 18.20% is 83.8% above this industry median. Based on the distribution chart, JMDC ranks #191 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, JMDC has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JMDC's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, JMDC ranks #191 out of 525 companies for 3-Year EBITDA Growth Rate. This puts JMDC in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. JMDC's value of 18.20% is 83.8% above this benchmark. Historically, JMDC's own 3-Year EBITDA Growth Rate has ranged from 11.00 to 37.80 over the past decade. While the company's 10-year median is 22.90 vs. the industry median of 9.90, JMDC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JMDC's current 3-Year EBITDA Growth Rate of 18.20% is 83.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for JMDC and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JMDC's current 3-Year EBITDA Growth Rate is 18.20%, which is 21% below median its own 10-year median of 22.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JMDC stock overvalued right now?
Based on GuruFocus' analysis, JMDC (FRA:6JM) is currently considered Significantly Undervalued. The stock's GF Value™ is €29.78, compared to a current price of €18.70 — trading 37.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 18.20%, which is 21% below median its 10-year median of 22.90 and 83.8% above the Healthcare Providers & Services industry median of 9.90. JMDC's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For JMDC (FRA:6JM), the current 3-Year EBITDA Growth Rate is 18.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JMDC (FRA:6JM) Overvalued in 2026?
Based on GuruFocus' analysis, JMDC stock appears to be undervalued.
The current stock price of €18.70 is trading 37.2% below its estimated GF Value™ of €29.78.
GuruFocus considers JMDC to be Significantly Undervalued.
Key valuation signals for FRA:6JM:
3-Year EBITDA Growth Rate: 18.20% (21% below median its 10-year median of 22.90)
GF Value™: €29.78 vs. price of €18.70 (37.2% below fair value)
Industry Position: 83.8% above the Healthcare Providers & Services median (#191 of 525)
No single metric tells the full story. See the FRA:6JM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JMDC Inc is engaged in constructing and providing a medical database, offering PHR and other health promotion services, telemedicine such as diagnostic imaging, and providing digital solutions to dispensing pharmacies.
80GF Score
Get the complete analysis for FRA:6JM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6JM has been successfully added to your 
